Results 141 to 150 of about 1,197 (187)
Some of the next articles are maybe not open access.
Journal of Clinical Sleep Medicine (JCSM)
The majority of patients with Prader-Willi syndrome experience excessive daytime sleepiness (EDS). This study evaluated the effects of pitolisant, a histamine 3 (H3)-receptor antagonist/inverse agonist that promotes wakefulness, in patients with Prader ...
Amee Revana +11 more
semanticscholar +1 more source
The majority of patients with Prader-Willi syndrome experience excessive daytime sleepiness (EDS). This study evaluated the effects of pitolisant, a histamine 3 (H3)-receptor antagonist/inverse agonist that promotes wakefulness, in patients with Prader ...
Amee Revana +11 more
semanticscholar +1 more source
Efficacy and safety of pitolisant in children above 6 years with narcolepsy
Expert Opinion on PharmacotherapyIntroduction The newly approved use of pitolisant in pediatric narcolepsy marks a significant advancement for patients and clinicians, given the scarcity of medications for this age group that are both safe and effective in reducing narcolepsy symptoms ...
Beatrice Bertini, Claudio Liguori
semanticscholar +1 more source
Drug and Therapeutics Bulletin, 2017
▼Pitolisant (Wakix—Bioprojet Pharma) is a new treatment for adults with narcolepsy with or without cataplexy. It was licensed for use in the EU in March last year and has orphan drug status.1 Here, we consider the evidence for pitolisant for the treatment of narcolepsy in adults and how it fits with current management strategies.
openaire +2 more sources
▼Pitolisant (Wakix—Bioprojet Pharma) is a new treatment for adults with narcolepsy with or without cataplexy. It was licensed for use in the EU in March last year and has orphan drug status.1 Here, we consider the evidence for pitolisant for the treatment of narcolepsy in adults and how it fits with current management strategies.
openaire +2 more sources
Sleep
Idiopathic Hypersomnia (IH) is a rare and chronic neurological disorder. People with IH experience severe excessive daytime sleepiness (EDS), sleep inertia, and a multitude of adverse functional outcomes.
Bruce C. Corser +11 more
semanticscholar +1 more source
Idiopathic Hypersomnia (IH) is a rare and chronic neurological disorder. People with IH experience severe excessive daytime sleepiness (EDS), sleep inertia, and a multitude of adverse functional outcomes.
Bruce C. Corser +11 more
semanticscholar +1 more source
Real-world treatment of pediatric narcolepsy with pitolisant: A retrospective, multicenter study.
Sleep Medicine, 2023BACKGROUND First symptoms of narcolepsy mostly present during childhood. Pharmacological management options in children are limited, also due to approval status.
A. Triller +8 more
semanticscholar +1 more source
Pitolisant and intravenous cocaine self-administration in mice
European Journal of Pharmacology, 2019Pitolisant, a selective inverse agonist for the histamine H3 receptor, is a new treatment for adults suffering from narcolepsy. Numerous studies have shown that striatal H3 receptors can modulate the activity of the dopamine mesolimbic system, a neuronal pathway that plays a crucial role in drug addiction.
Benjamin, Huyts +2 more
openaire +2 more sources
Sleep
Pitolisant is FDA approved for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy and for the treatment of EDS in pediatric patients ≥6 years with narcolepsy.
D. Plante +11 more
semanticscholar +1 more source
Pitolisant is FDA approved for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy and for the treatment of EDS in pediatric patients ≥6 years with narcolepsy.
D. Plante +11 more
semanticscholar +1 more source
Sleep Medicine
BACKGROUND Restless leg syndrome (RLS) treatments include iron, dopaminergics, gabapentinoids, and opioids, but symptoms often become refractory over time. Sedating antihistamines, which cross the blood-brain border, frequently exacerbate RLS. Pitolisant
William G Ondo
semanticscholar +1 more source
BACKGROUND Restless leg syndrome (RLS) treatments include iron, dopaminergics, gabapentinoids, and opioids, but symptoms often become refractory over time. Sedating antihistamines, which cross the blood-brain border, frequently exacerbate RLS. Pitolisant
William G Ondo
semanticscholar +1 more source
The Annals of Pharmacotherapy
Objective: To assess the efficacy and safety of pitolisant, a selective histamine H₃ receptor antagonist/inverse agonist, for excessive daytime sleepiness (EDS) in narcolepsy or obstructive sleep apnea (OSA).
A. Jalal +6 more
semanticscholar +1 more source
Objective: To assess the efficacy and safety of pitolisant, a selective histamine H₃ receptor antagonist/inverse agonist, for excessive daytime sleepiness (EDS) in narcolepsy or obstructive sleep apnea (OSA).
A. Jalal +6 more
semanticscholar +1 more source
Clinical and experimental pathology
The study of neuropathophysiological mechanisms of epileptic activity that occur with the participation of the brain’s endogenous histaminergic system makes it possible to substantiate effective, complex means of controlling seizure manifestations and ...
O. Yehorenko, M. Pervak
semanticscholar +1 more source
The study of neuropathophysiological mechanisms of epileptic activity that occur with the participation of the brain’s endogenous histaminergic system makes it possible to substantiate effective, complex means of controlling seizure manifestations and ...
O. Yehorenko, M. Pervak
semanticscholar +1 more source